Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.

Abstract

Mirvetuximab soravtansine in combination with bevacizumab (Avastin) to treat patients with platinum-agnostic ovarian cancer demonstrated a confirmed 64% overall response rate (ORR), regardless of platinum status, according to study results presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

• Authors: Matthew Fowler
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 34 Issue 7 Pg. 250 (Jul 15 2020) ISSN: 0890-9091 [Print] United States
• PMID: 32674207 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Immunoconjugates
• Organoplatinum Compounds
• Maytansine
• Bevacizumab
• mirvetuximab soravtansine

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bevacizumab (administration & dosage, adverse effects)
• Carcinoma, Ovarian Epithelial (drug therapy, metabolism, pathology)
• Drug Resistance, Neoplasm
• Female
• Humans
• Immunoconjugates (administration & dosage, adverse effects)
• Maytansine (administration & dosage, adverse effects, analogs & derivatives)
• Middle Aged
• Organoplatinum Compounds (administration & dosage)
• Ovarian Neoplasms (drug therapy, metabolism, pathology)